Table 1.
Characteristics of four European panels of asthmatic/COPD patients
| |
Helsinki |
Athens |
Amsterdam |
Birmingham |
||||
|---|---|---|---|---|---|---|---|---|
| n = 36a | n = 35a | n = 36a | n = 29a | |||||
| Male /Female |
6 / 30 |
19 / 16 |
10 / 26 |
7 / 22 |
||||
| Asthma |
3 / 28 |
6 / 13 |
3 / 8 |
6 / 21 |
||||
| COPD |
3 / 1 |
12 / 3 |
2 / 7 |
1 / 0 |
||||
| Otherb |
0 / 1 |
1 / 0 |
5 / 11 |
0 / 1 |
||||
| Agec |
63.5 |
[36–85] |
62.2 |
[33–84] |
63.3 |
[46–77] |
60.1 |
[37–76] |
| Asthma |
62.9 |
[36–85] |
55.7 |
[33–77] |
62.8 |
[46–77] |
59.6 |
[37–76] |
| COPD |
65.0 |
[57–74] |
68.7 |
[45–84] |
63.7 |
[59–72] |
53.0 |
- |
| Otherb |
75.0 |
- |
78.0 |
- |
63.2 |
[46–77] |
69.0 |
- |
| Asthma |
31 |
(86%) |
19 |
(54%) |
11 |
(31%) |
27 |
(93%) |
| COPD |
4 |
(11%) |
15 |
(43%) |
9 |
(25%) |
1 |
(3.5%) |
| Asthma + COPD |
1 |
(3%) |
1 |
(3%) |
4 |
(11%) |
1 |
(3.5%) |
| CNSLDd |
0 |
(0%) |
0 |
(0%) |
12 |
(33%) |
0 |
(0%) |
|
Smoking status | ||||||||
| Never smoker |
26 |
(72%) |
15 |
(43%) |
13 |
(36%) |
15 |
(52%) |
| Current |
0 |
(0%) |
1 |
(3%) |
0 |
(0%) |
3 |
(10%) |
| Ex-smoker |
10 |
(28%) |
19 |
(54%) |
23 |
(64%) |
11 |
(48%) |
| ETSe exposure at home |
0 |
(0%) |
5 |
(14.7%) |
0 |
(0%) |
1 |
(3.4%) |
|
Medication use | ||||||||
| Short acting β2-agonist |
24 |
(67%) |
9 |
(26%) |
16 |
(44%) |
28 |
(97%) |
| Reliever medicationf |
29 |
(81%) |
21 |
(62%) |
25 |
(69%) |
29 |
(100%) |
| Inhaled glucocorticosteroids |
34 |
(94%) |
28 |
(82%) |
27 |
(75%) |
24 |
(83%) |
| Oral glucocorticosteroids |
5 |
(14%) |
5 |
(15%) |
6 |
(17%) |
6 |
(21%) |
|
On need medication use | ||||||||
| Short acting β2-agonist |
18 |
(50%) |
8 |
(24%) |
14 |
(39%) |
28 |
(97%) |
| Reliever medicationf |
22 |
(61%) |
21 |
(62%) |
18 |
(50%) |
29 |
(100%) |
| Inhaled glucocorticosteroids |
6 |
(17%) |
18 |
(53%) |
7 |
(19%) |
5 |
(17%) |
| Oral glucocorticosteroids | 3 | (8%) | 5 | (15%) | 4 | (11%) | 5 | (17%) |
a Total participants in panel.
b Asthma + COPD or chronic non-specific lung disease.
c Given as mean and [range].
d Chronic non-specific lung disease.
e Environmental tobacco smoke.
f Includes short acting β2-agonist, long acting β2-agonist, anticholinergic drugs and combination of an anticholinergic drug and a β2-agonist.